These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32565294)

  • 1. Effective-constituent compatibility-based analysis of Bufei Yishen formula, a traditional herbal compound as an effective treatment for chronic obstructive pulmonary disease.
    Li JS; Liu XF; Dong HR; Zheng WC; Feng SX; Tian YG; Zhao P; Ma JD; Ren ZX; Xie Y
    J Integr Med; 2020 Jul; 18(4):351-362. PubMed ID: 32565294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective-component compatibility of Bufei Yishen formula II inhibits mucus hypersecretion of chronic obstructive pulmonary disease rats by regulating EGFR/PI3K/mTOR signaling.
    Li J; Ma J; Tian Y; Zhao P; Liu X; Dong H; Zheng W; Feng S; Zhang L; Wu M; Zhu L; Liu S; Zhao D
    J Ethnopharmacol; 2020 Jul; 257():112796. PubMed ID: 32344236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Compatibility characteristics of Bufei Yishen formula III in regulating chronic obstructive pulmonary disease mucus hypersecretion].
    Qin Y; Li M; Tian Y; Zhao P; Li K; Li C; Li J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Nov; 33(11):1309-1314. PubMed ID: 34980299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective-Component Compatibility of Bufei Yishen Formula III Combined with Electroacupuncture Suppresses Inflammatory Response in Rats with Chronic Obstructive Pulmonary Disease via Regulating SIRT1/NF-
    Jin F; Zhang L; Chen K; Miao Y; Liu Y; Tian Y; Li J
    Biomed Res Int; 2022; 2022():3360771. PubMed ID: 35586807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism underlying the therapeutic effects of effective component compatibility of Bufei Yishen formula III combined with exercise rehabilitation on chronic obstructive pulmonary disease.
    Huang L; Guan Q; Lu R; Zhang Z; Liu C; Tian Y; Li J
    Ann Med; 2024 Dec; 56(1):2403729. PubMed ID: 39276358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective-Component Compatibility of Bufei Yishen Formula III Suppresses Mitochondrial Oxidative Damage in COPD: Via Pkm2/Nrf2 Pathway.
    Liu Y; Zhang L; Zhao J; Lu R; Shao X; Xu K; Li J; Tian Y
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1905-1920. PubMed ID: 39206144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective-component compatibility of Bufei Yishen formula alleviates chronic obstructive pulmonary disease inflammation by regulating GSK3β-mediated NLRP3 inflammasome activation.
    Qin Y; Zhai J; Yang J; Li H; Tian Y; Liu X; Zhao P; Li J
    Biomed Pharmacother; 2023 Dec; 168():115614. PubMed ID: 37862971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Component Compatibility of Bufei Yishen Formula III Which Regulates the Mucus Hypersecretion of COPD Rats via the miR-146a-5p/EGFR/MEK/ERK Pathway.
    Ma J; Liu X; Wei Y; Lu R; Xu K; Tian Y; Li J
    Evid Based Complement Alternat Med; 2022; 2022():9423435. PubMed ID: 36619199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective-component compatibility of Bufei Yishen formula III ameliorated COPD by improving airway epithelial cell senescence by promoting mitophagy via the NRF2/PINK1 pathway.
    Li MY; Qin YQ; Tian YG; Li KC; Oliver BG; Liu XF; Zhao P; Li JS
    BMC Pulm Med; 2022 Nov; 22(1):434. PubMed ID: 36414945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective-compound combination of Bufei Yishen formula III combined with ER suppress airway mucus hypersecretion in COPD rats: via EGFR/MAPK signaling.
    Xu K; Ma J; Lu R; Shao X; Zhao Y; Cui L; Qiu Z; Tian Y; Li J
    Biosci Rep; 2023 Nov; 43(11):. PubMed ID: 36799253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease.
    Li J; Zhao P; Li Y; Tian Y; Wang Y
    Sci Rep; 2015 Oct; 5():15290. PubMed ID: 26469778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring Th17/Treg balance via modulation of STAT3 and STAT5 activation contributes to the amelioration of chronic obstructive pulmonary disease by Bufei Yishen formula.
    Zhao P; Li J; Tian Y; Mao J; Liu X; Feng S; Li J; Bian Q; Ji H; Zhang L
    J Ethnopharmacol; 2018 May; 217():152-162. PubMed ID: 29454913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38.
    Li J; Xie Y; Zhao P; Qin Y; Oliver BG; Tian Y; Li S; Wang M; Liu X
    Phytomedicine; 2021 Mar; 83():153475. PubMed ID: 33545548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen formula for the treatment of chronic obstructive pulmonary disease.
    Zhao P; Li J; Yang L; Li Y; Tian Y; Li S
    Mol Med Rep; 2018 Apr; 17(4):5247-5257. PubMed ID: 29393428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective-component compatibility of Bufei Yishen formula protects COPD rats against PM2.5-induced oxidative stress via miR-155/FOXO3a pathway.
    Li J; Wang J; Li Y; Zhao P; Tian Y; Liu X; He H; Jia R
    Ecotoxicol Environ Saf; 2021 Nov; 228():112918. PubMed ID: 34773846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. System biology analysis of long-term effect and mechanism of Bufei Yishen on COPD revealed by system pharmacology and 3-omics profiling.
    Li J; Zhao P; Yang L; Li Y; Tian Y; Li S
    Sci Rep; 2016 May; 6():25492. PubMed ID: 27146975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective-components combination alleviates PM2.5-induced inflammation by evoking macrophage autophagy in COPD.
    Wang J; He W; Yue H; Zhao P; Li J
    J Ethnopharmacol; 2024 Mar; 321():117537. PubMed ID: 38043756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of airway epithelial barrier integrity via the inhibition of AHR/EGFR activation ameliorates chronic obstructive pulmonary disease using effective-component combination.
    Wei Y; Liu X; Jiang Y; Guan Q; Tian Y; Li J; Zhao P
    Phytomedicine; 2023 Sep; 118():154980. PubMed ID: 37499344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bufei Yishen granules combined with acupoint sticking therapy suppress oxidative stress in chronic obstructive pulmonary disease rats: Via regulating peroxisome proliferator-activated receptor-gamma signaling.
    Li Y; Tian YG; Li JS; Dong YQ; Wang MH; Feng SX; Li LL; Mao J; Wang LL; Luo S
    J Ethnopharmacol; 2016 Dec; 193():354-361. PubMed ID: 27562320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bufei Yishen formula protects the airway epithelial barrier and ameliorates COPD by enhancing autophagy through the Sirt1/AMPK/Foxo3 signaling pathway.
    Jia L; Liu X; Liu X; Guan Q; Tian Y; Li J; Zhao P
    Chin Med; 2024 Feb; 19(1):32. PubMed ID: 38413976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.